Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases

Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine...

Full description

Bibliographic Details
Main Authors: Singh R, Pervin S, Lee S, Kuo A, Grijalva V, David J, Vergnes L, Reddy ST
Format: Article
Language:English
Published: Dove Medical Press 2018-03-01
Series:Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:
Online Access:https://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSO
id doaj-205fa0d3ae934c8c9884377911147ff2
record_format Article
spelling doaj-205fa0d3ae934c8c9884377911147ff22020-11-25T00:29:59ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy1178-70072018-03-01Volume 11658437419Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseasesSingh RPervin SLee SKuo AGrijalva VDavid JVergnes LReddy STRajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; 3The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; 4Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, CT, USA; 5Department of Biology, California State University Dominguez Hills, CA, USA; 6Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA; 7Department of Comparative Medicine, Pfizer Inc, San Diego, CA, USA; 8Department of Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells.Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention. Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQhttps://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSOFollistatinBrowningObesityMetabolic profilingMetabolic Diseases
collection DOAJ
language English
format Article
sources DOAJ
author Singh R
Pervin S
Lee S
Kuo A
Grijalva V
David J
Vergnes L
Reddy ST
spellingShingle Singh R
Pervin S
Lee S
Kuo A
Grijalva V
David J
Vergnes L
Reddy ST
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Follistatin
Browning
Obesity
Metabolic profiling
Metabolic Diseases
author_facet Singh R
Pervin S
Lee S
Kuo A
Grijalva V
David J
Vergnes L
Reddy ST
author_sort Singh R
title Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_short Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_full Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_fullStr Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_full_unstemmed Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_sort metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
publisher Dove Medical Press
series Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
issn 1178-7007
publishDate 2018-03-01
description Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; 3The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; 4Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, CT, USA; 5Department of Biology, California State University Dominguez Hills, CA, USA; 6Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA; 7Department of Comparative Medicine, Pfizer Inc, San Diego, CA, USA; 8Department of Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells.Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention. Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQ
topic Follistatin
Browning
Obesity
Metabolic profiling
Metabolic Diseases
url https://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSO
work_keys_str_mv AT singhr metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT pervins metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT lees metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT kuoa metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT grijalvav metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT davidj metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT vergnesl metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
AT reddyst metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
_version_ 1725328621556465664